Are laboratory investigations recommended in current medical practice guidelines supported by available evidence?

Clinical Chemistry and Laboratory Medicine

Volumn 40, Issue 3, 2002, Pages 252-255

  Watine, Joseph ^a  

^a HÔPITAL DU BOCAGE   (France)

Author keywords

Clinical trials; Evidence based laboratory medicine; Non small cell lung cancer; Practice guidelines

Indexed keywords

ALBUMIN; CA 125 ANTIGEN; CALCIUM; CARCINOEMBRYONIC ANTIGEN; CYTOKERATIN 19 FRAGMENT; LACTATE DEHYDROGENASE; NEURON SPECIFIC ENOLASE; TISSUE POLYPEPTIDE ANTIGEN; TUMOR MARKER;

ACCURACY; ARTICLE; BLOOD CELL COUNT; CANCER PATIENT; CANCER STAGING; CLINICAL PRACTICE; CLINICAL TRIAL; EUROPE; EVIDENCE BASED MEDICINE; FRANCE; HUMAN; LABORATORY TEST; LUNG NON SMALL CELL CANCER; MEDICAL EXAMINATION; MEDICAL SOCIETY; PATIENT SELECTION; PRACTICE GUIDELINE; PRIORITY JOURNAL; PROGNOSIS; UNITED STATES;

CALCIUM; CARCINOMA, NON-SMALL-CELL LUNG; CHEMISTRY, CLINICAL; EVIDENCE-BASED MEDICINE; GUIDELINES; HUMANS; LUNG NEOPLASMS; PROGNOSIS; SERUM ALBUMIN; TUMOR MARKERS, BIOLOGICAL;

EID: 0036239069     PISSN: 14346621     EISSN: None     Source Type: Journal    
DOI: 10.1515/CCLM.2002.041     Document Type: Article

References (19)

1. Which guidelines can we trust? Assessing strength of evidence behind recommendations for clinical practice
2. Further disquiet on the guidelines front
3. Les recommendations des "sociétés savantes" et leurs bases scientifiques
4. Evidence based medicine: What it is and what it isn't
5. Training and practice in evidence based laboratory medicine
6. Evidence-based medicine: Its application to laboratory medicine
7. Evidence-based laboratory medicine: Supporting decision-making
8. Pretreatment evaluation of non-small-cell lung cancer
9. Tumour markers in lung cancer: EGTM recommendations
10. Recommendations concernant l'utilisation des marqueurs tumoraux sériques dans la prise en charge des cancers bronchiques primitifs
11. Prognostic evaluation of primary non-small cell lung carcinoma patients using biological fluid variables. A systematic review
12. Toward a checklist for reporting of studies of diagnostic accuracy of medical tests
13. Analyse bibliographique quantitative de la recherche clinique française en thérapeutique des cancers broncho-pulmonaires
14. The CONSORT statement: Revised recommendations for improving the quality of reports of parallel-group randomized trials
15. The future of prognostic factors in outcome prediction for patients with cancer
16. Serum Cyfra 21-1 as a co-variable in future NSCLC chemotherapy trials
17. Cytokeratins as serum markers in lung cancer: A comparison of CYFRA 21-1 and TPS
18. Confirmation of a prognostic index for patients with inoperable non-small cell lung cancer
19. Comments on: Anemia as an independent prognostic factor for survival in patients with cancer